Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responsesMarcin Kortylewski, Hua Yu, Heehyoung Lee et al.|Nature Biotechnology|2009Cited by 378
Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer CellsHarris S. Soifer, Cy A. Stein|Journal of Biological Chemistry|2011Cited by 81